Veracity Capital LLC Has $807,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Veracity Capital LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 58.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,733 shares of the biopharmaceutical company’s stock after purchasing an additional 3,213 shares during the period. Veracity Capital LLC’s holdings in Gilead Sciences were worth $807,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Bellevue Group AG increased its stake in shares of Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after acquiring an additional 7,093 shares in the last quarter. Quantinno Capital Management LP increased its stake in Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares in the last quarter. Legal & General Group Plc increased its stake in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC acquired a new position in shares of Gilead Sciences during the third quarter valued at about $830,000. Finally, Capital Investment Advisors LLC grew its stake in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after buying an additional 9,791 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $92.92 on Friday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $115.80 billion, a PE ratio of 1,032.44, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The stock has a 50-day moving average price of $91.63 and a 200-day moving average price of $84.63.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 earnings per share. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 456,234 shares of company stock valued at $42,130,461 over the last 90 days. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several recent research reports. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. BMO Capital Markets increased their target price on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $87.00 to $113.00 in a research note on Friday, January 10th. Piper Sandler raised their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Bank of America restated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.